KLOX Technologies reports on final results from its clinical study on LumiHeal(TM) for the treatment of chronic wounds
LAVAL, Quebec, May 03, 2017 (GLOBE NEWSWIRE) -- Today, the final results on KLOX Technologies' (Klox) EUREKA study, which evaluated LumiHeal in the treatment of hard-to-heal, non-responsive, chronic wounds, were reported at the European Wound Management Association, in Amsterdam.
LumiHeal is a CE marked, first-in-class, proprietary, non-thermal and non-invasive treatment solution that utilizes hyper pulsed fluorescence light (HPFL) to treat acute and chronic wounds.
"LumiHeal has shown that it is a viable and effective treatment solution for patients with debilitating hard-to-heal, chronic wounds," stated Dr. Marco Romanelli, MD, PhD, Associate Professor of Dermatology at the School of Medicine, University of Pisa, and Chief of the Wound Healing Research Unit, and President Elect of the World Union of Wound Healing Societies. "LumiHeal represents a new option in the way practitioners can manage and treat hard-to-heal chronic wounds."
"We are very pleased that the data released today confirmed the interim analysis reported in September 2016 on 33 patients," said Dr. Michel Cimon, MD, Senior Vice President, Chief Medical and Scientific Officer at Klox. "It's an important day for LumiHeal and for FB Advanced Wound Care, our wound care franchise."
Clinical final results from EUREKA study on LumiHeal(TM) and chronic wounds management
Professor Marco Romanelli reported the final study results on the evaluation of real-life use of LumiHeal in Chronic Wounds Management (Venus Leg Ulcers, Diabetic Foot Ulcers, and Pressure Ulcers). The results reported were on 99 patients who completed treatment in the EUREKA study.
Investigators' final analysis supports the strong efficacy profile of LumiHeal in promoting wound closure along with wound bed preparation in hard-to-heal chronic wounds. These results indicate LumiHeal's ability, in a majority of cases, to transition hard-to-heal, non-responsive, chronic wounds into an acute wound setting.
Investigators found the treatment to be safe, easy to administer and very well tolerated by the subjects' population. Compliance to the study visits was excellent.
The excellent tolerability and compliance profiles is reinforced by the positive action on pain reduction observed during this study, especially in the VLU population.
Final results show:
Out of the 99 patients reported, 71% of them had a prognosis factor of poor healing at study entry;
The average treatment duration for all types of wounds was 80.5 days;
47 of these hard-to heal, chronic wounds, closed completely during the study period VLUs (26), DFUs (16), PU (5);
96% of wounds that closed completely, remained closed throughout the follow up period;
69.2% of VLUs and 68.8% of DFUs were ready for skin graft according to clinician's opinion;
The table below summarizes the top line data:
at last Study
The final results of the EUREKA study show, that taken together with efficacy, treatment ease of use, safety, and a positive impact on pain reduction, LumiHeal has the ability to become a leading option for the treatment and management of hard-to-heal, chronic wounds.
LumiHeal is a CE marked, first-in-class, proprietary, non-thermal and non-invasive treatment solution that generates hyper pulsed fluorescence light to treat acute and chronic wounds. It is used in conjunction with a multi-LED light. LumiHeal is a topical gel comprising of light absorbing molecules, which is applied to a wounded area. The HPFL generated have the capacity to penetrate various depths of the skin (epidermis, dermis, hypodermis). Treatment duration lasts only a number of minutes, while maintaining a safe and well tolerated product profile.
About KLOX Technologies
Klox is a specialty pharmaceutical company focused on developing and commercializing products based on its proprietary Fluorescence Biomodulation technology platform, previously known as BioPhotonics, to address skin and soft tissue disorders. Klox is advancing its programs as part of its multiple franchises focusing on indications across Dermatology, Wound Care, and Oral Health. For more information and to consult the abstracts, please visit www.kloxtechnologies.com.
Forward Looking Statements
Certain statements contained in this newswire, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward looking statements include those regarding cosmetics and medical devices and medical applications and clinical trials and the status and related results thereto, as well those regarding continuing and further development and commercialization efforts. Such statements, based as they are on the current analysis and expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Klox Technologies Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the medical, cosmetics and/or consumer goods industries, changes in the regulatory environment in the jurisdictions in which Klox Technologies Inc. does business, financial and commercial markets volatility, fluctuations in costs, and changes to the competitive environment, as well as other risks. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. In the case of forward-looking statements regarding investigational product candidates and continuing and further development efforts, specific risks which could cause actual results to differ materially from Klox Technologies Inc.'s current analysis and expectations include: failure to demonstrate the safety, tolerability and efficacy of our products, final and quality controlled verification of data and the related analyses, and the expense and uncertainty of obtaining regulatory approval.
For more information:
Jade Lavallée Labossière
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: KLOX Technologies Inc. via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
Senegal and France to host Global Partnership for Education Financing Conference20.9.2017 23:00 | Pressmeddelande
NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE) -- The Global Partnership for Education (GPE) is delighted that the governments of Senegal and France will co-host its financing conference, which will take place on February 8, 2018 in Dakar, Senegal. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d3003cff-ee20-409f-9729-9a9cef1d4d3e A video accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0a7eebb6-66b3-438b-904e-efeff83d94cf The announcement of the co-hosting was made by Presidents Macky Sall of Senegal and Emmanuel Macron of France at a high-level event on education financing held at the United Nations, which was attended by Secretary General António Guterres, several heads of state and leaders on global education. " The Global Partnership for Education has made substantial investments in education helpin
K2 Launches New Process Automation Platform Including New Cloud Service20.9.2017 18:00 | Pressmeddelande
K2's process automation platform allows businesses of all types around the globe to rapidly build and deploy automation across the business. BELLEVUE, Wash., Sept. 20, 2017 (GLOBE NEWSWIRE) -- K2 today announced the availability of its new low-code process automation platform - furthering innovation in the way organizations drive digital efficiencies. With a new managed cloud service, K2 Cloud, new on-premises version, K2 Five, and completely redesigned user interfaces and experiences, the platform helps businesses of all types around the globe rapidly deliver powerful process automation and realize business productivity gains. Automating business processes across an enterprise is crucial to the success of companies in the era of digital transformation. However, many initiatives are impacted by a lack of sufficient resources and the use of inefficient systems to manage processes. K2's low-code process automation platform solves these problems by enabling organ
8x8 and Aryaka Partner to Enhance Cloud Communications for Global Enterprises20.9.2017 16:43 | Pressmeddelande
Strategic Alliance will improve communications experience for business users worldwide SAN MATEO, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Aryaka®, the leading global SD-WAN provider, and 8x8, Inc. (NASDAQ:EGHT), the world's first Communications Cloud provider, today announced that they are entering a strategic partnership that will improve the performance and reliability of business-critical cloud unified communications. This will enable global mid-market and enterprise companies to enhance business communications, collaboration and customer engagement for their employees, customers and partners around the world. Through this partnership, Aryaka's global SD-WAN solution will provide enterprise-grade private connectivity to further enhance the superior voice and video quality delivered by the 8x8 Communications Cloud(TM). When tested against several leading Unified Communications as a Service (UCaaS) providers, 8x8 was recently found by the Tolly Group to deliver the hi
NRT Technology Corp and Gaming Payments Innovator Sightline Payments Announce Merger20.9.2017 16:00 | Pressmeddelande
Combination Will Accelerate Innovation in Mobile, Data, Cashless Payments, and Provisional Credit Solutions to the Worldwide Integrated Resort Casino Industry LAS VEGAS, Sept. 20, 2017 (GLOBE NEWSWIRE) -- NRT Technology Corp. ("NRT") a leading provider of integrated ticket redemption and payment services to global casino operators, and Sightline Payments ("Sightline"), developers of the disruptive Play+ platform that's powering the next generation of cashless and mobile gaming payment solutions, announced today an agreement to merge. The company on closing will be named NRT Sightline and will form one of the largest pure play gaming payment technology companies in the world with an equity value of over $300 million. Following the closing of the transaction and subject to regulatory approvals, Sightline's CEO and Founder, Kirk Sanford, will assume the role of President and CEO of NRT Sightline. NRT's current Founder, P
BT and Hitachi Partner to Develop Industrial and Enterprise IOT Solutions20.9.2017 15:00 | Pressmeddelande
Initial Focus on Asset Intelligence and Predictive Maintenance Use Cases LAS VEGAS and LONDON, Sept. 20, 2017 (GLOBE NEWSWIRE) -- BT, one of the world's leading providers of communications services and solutions, and Hitachi Vantara, a wholly owned subsidiary of Hitachi Ltd. (TSE:6501) today announced a global partnership to co-create innovative solutions in the area of industrial and enterprise internet of things (IoT). The partnership aims to drive better business outcomes for global customers, including greater efficiency, productivity and cost savings. The companies will initially focus on exploring and designing asset intelligence and predictive maintenance solutions to deliver the desired outcomes for customers in industry sectors such as manufacturing and transportation. Announced at Hitachi's inaugural user conference, Hitachi NEXT 2017, in Las Vegas today, the partnership unites BT's global network infrastructure, cloud capabiliti
XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer20.9.2017 14:00 | Pressmeddelande
AUSTIN, Texas, Sept. 20, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today its agreement with Cedars-Sinai Medical Center located in Los Angeles, California, whereby XBiotech will provide its interleukin-1 alpha antagonist, MABp1, for a Phase I single arm study evaluating the maximum tolerated dose of Onivyde® (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The study will also assess efficacy using various secondary measures including changes in lean body mass, weight stability, IL-6 levels, overall and progression free survival as well as evaluation of the relationship between treatment tolerance and patient functional status. Andrew Hendifar, M.D., Medical Oncology lead for the Gastrointestinal Disease Research Group at Cedars-Sinai and Co-Director of Pancreas Oncology, will be leading the study which is planned to enroll a total of 16 pati
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum